I'm LongbridgeAI, I can summarize articles.BeOne Medicines (ONC.US) rose nearly 2% in overnight trading to a record high of $428.17.
The stock is up 13.34% over the past five sessions and up 40.94% year to date. It sits 68.61% above its 52-week low of US$253.94.
The Nasdaq Composite is down 1.05% over the past five sessions and up 9.57% year to date.
China's Center for Drug Evaluation proposed on Nov. 9 to grant priority review to daraxonrasib tablets for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are unsuitable for multi-drug combination regimens.
Separately, the company reported first-nine-month revenue of 34.993 billion yuan, up 26.8% from a year earlier, while net income attributable to shareholders surged 431.8% to 6.055 billion yuan. Driven by strong sales of its core product Brukinsa, BeOne raised its full-year 2026 revenue guidance to $6.9 billion to $7.0 billion.
Based on public media reports. AI-generated; not investment advice.
